Drugs / Elibulin
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06636981 | Nov 2024 → Sep 2029 expected | triple-negative breast carcinoma | Fudan University | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Elibulin | “Elibulin 1.4mg/m2 D1, 8 intravenous infusions, 1 course of treatment every 21 days” NCT06636981 ↗ |
| Route | Intravenous | “Elibulin 1.4mg/m2 D1, 8 intravenous infusions” NCT06636981 ↗ |